中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (3): 226-228.doi: 10.35541/cjd.20190100

• 临床经验 • 上一篇    下一篇

联合或者单独使用利伐沙班治疗青斑样血管病三例

饶诗佳1    李吉2    谢红付2    施为2    陆前进1   

  1. 1中南大学湘雅二医院皮肤科，长沙  410011；2中南大学湘雅医院皮肤科，长沙  410008 
  • 收稿日期:2018-12-10 修回日期:2019-09-16 发布日期:2020-03-03
  • 通讯作者: 施为；陆前进 E-mail:shiwei@csu.edu.cn; qianlu5860@csu.edu.cn

Successful treatment of three cases of livedoid vasculopathy with rivaroxaban alone or in combination

Rao Shijia1, Li Ji2, Xie Hongfu2, Shi Wei2, Lu Qianjin1   

  1. 1Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; 2Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China
  • Received:2018-12-10 Revised:2019-09-16 Published:2020-03-03
  • Contact: Shi Wei; Lu Qianjin E-mail:shiwei@csu.edu.cn; qianlu5860@csu.edu.cn

PDF

5

PDF (Mobile)

0

摘要： 【摘要】 青斑样血管病是一种皮肤浅层血管丛微血管血栓导致的慢性皮肤缺血坏死性疾病，该病少见且缺乏有效的治疗手段。抗凝药物治疗该病的有效性得到公认，但广泛应用受到用药途径及不良反应的影响。Xa因子抑制剂利伐沙班可用于预防及治疗血栓及因此造成的溃疡，无需监测凝血功能，不良反应少，口服方便。我们联合或单独使用利伐沙班治疗3例青斑样血管病，取得满意效果。

关键词: 皮肤疾病, 血管性； 抗凝药； 治疗结果； 青斑样血管病； 利伐沙班

Abstract: 【Abstract】 Livedoid vasculopathy is a rare chronic ischemic necrotic skin disease caused by microvascular thrombosis in superficial vascular plexuses. Effective treatments are lacking. Efficacy of anticoagulants has been clinically proven in the treatment of this disease, but the administration route and adverse reactions limit their extensive application. The new oral factor Xa inhibitor rivaroxaban, which has many advantages, such as no need for coagulation monitoring, few adverse reactions and convenient oral administration, can be used in the prevention and treatment of thrombosis and post-thrombotic ulcers, and it . In this article, 3 patients with livedoid vasculopathy were treated with rivaroxaban alone or in combination, and satisfactory efficacy was obtained.

Key words: Skin diseases, vascular, Anticoagulants, Treatment outcome, Livedoid vasculopathy, Rivaroxaban